超碰国产精品久久,欧美日韩一本二本,日韩午夜成人一区二区

Rongchang Biopharma H1 2025 Financial Report Rongchang Biopharma Rongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.
Dizal Pharma H1 2025 Financial Report Dizal Pharma Dizal Pharma reports its strongest half-year results in history, achieving first commercialization profit, accelerating R&D, and advancing global expansion with FDA-approved therapies.
Sino Biopharmaceutical H1 2025 Financial Report Sino Biopharmaceutical Sino Biopharmaceutical reported RMB 17.57B revenue in 1H 2025, up 10.7%. Innovative products grew 27.2% to RMB 7.80B. R&D investment hit RMB 3.19B, with multiple new drug approvals and acquisitions.
WuXi XDC H1 2025 Financial Report WuXi XDC WuXi XDC's 2025 half-year report: revenue RMB 2.701B (+62.2%), net profit RMB 746M (+52.7%), 563 global customers, 225 iCMC projects, backlog USD 1.329B, major capacity expansion in Wuxi and Singapore.
CARsgen Therapeutics H1 2025 Financial Report CARsgen CARsgen Therapeutics 2025 H1 results: revenue RMB 509.61M (+703.8% YoY), driven by BCMA CAR-T ZeKeze?. Pipeline updates include CT041 NDA acceptance, solid tumor CAR-T breakthroughs, and multiple allogeneic CAR-T developments.
Wanhua Chemical H1 2025 Financial Report Wanhua Chemical Group Wanhua Chemical posted H1 2025 revenue of RMB 90.9B, down 6.35%, with net profit down 25.1%. Business performance varied across polyurethane, petrochemical, and new materials segments.
Gilead Q2 2025 Financial Report Financial statements Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
Sutro Biopharma H1 2025 Financial Report Financial statements Sutro Biopharma rebounds after major restructuring, posting 110% H1 2025 revenue growth. With strong cash reserves, strategic ADC pipeline advances, and key partnerships, it targets critical milestones through 2027.
BeOne(BeiGene) Q2 2025 Interim Financial Report BeiGene BeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
2025 H1 Global Pharma Earnings Panorama Financial statements A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.

< Pre 1 234 5 6 7 8...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水